ES2332062T3 - Micelas polimericas para el suministro de farmacos. - Google Patents

Micelas polimericas para el suministro de farmacos. Download PDF

Info

Publication number
ES2332062T3
ES2332062T3 ES06749187T ES06749187T ES2332062T3 ES 2332062 T3 ES2332062 T3 ES 2332062T3 ES 06749187 T ES06749187 T ES 06749187T ES 06749187 T ES06749187 T ES 06749187T ES 2332062 T3 ES2332062 T3 ES 2332062T3
Authority
ES
Spain
Prior art keywords
group
side chain
quad
protected
saturated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06749187T
Other languages
English (en)
Spanish (es)
Inventor
Kurt Breitenkamp
Kevin Sill
Habib Skaff
Rebecca Breitenkamp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intezyne Technologies Inc
Original Assignee
Intezyne Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intezyne Technologies Inc filed Critical Intezyne Technologies Inc
Application granted granted Critical
Publication of ES2332062T3 publication Critical patent/ES2332062T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/40—Polyamides containing oxygen in the form of ether groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/028—Polyamidoamines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nanotechnology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
ES06749187T 2005-04-01 2006-04-03 Micelas polimericas para el suministro de farmacos. Active ES2332062T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66726005P 2005-04-01 2005-04-01
US667260P 2005-04-01
US74178005P 2005-12-01 2005-12-01
US741780P 2005-12-01

Publications (1)

Publication Number Publication Date
ES2332062T3 true ES2332062T3 (es) 2010-01-25

Family

ID=36951510

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06749187T Active ES2332062T3 (es) 2005-04-01 2006-04-03 Micelas polimericas para el suministro de farmacos.

Country Status (13)

Country Link
US (6) US7638558B2 (US07638558-20091229-C00193.png)
EP (1) EP1907444B1 (US07638558-20091229-C00193.png)
JP (1) JP4390845B2 (US07638558-20091229-C00193.png)
KR (1) KR101288729B1 (US07638558-20091229-C00193.png)
AT (1) ATE440117T1 (US07638558-20091229-C00193.png)
AU (1) AU2006231452B2 (US07638558-20091229-C00193.png)
CA (1) CA2603853C (US07638558-20091229-C00193.png)
DE (1) DE602006008625D1 (US07638558-20091229-C00193.png)
ES (1) ES2332062T3 (US07638558-20091229-C00193.png)
IL (1) IL186254A (US07638558-20091229-C00193.png)
MX (1) MX2007012157A (US07638558-20091229-C00193.png)
NZ (1) NZ562064A (US07638558-20091229-C00193.png)
WO (1) WO2006107903A2 (US07638558-20091229-C00193.png)

Families Citing this family (198)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080281041A1 (en) 1999-06-07 2008-11-13 Rozema David B Reversibly Masked Polymers
US8138383B2 (en) * 2002-03-11 2012-03-20 Arrowhead Madison Inc. Membrane active heteropolymers
US8008355B2 (en) * 2002-03-11 2011-08-30 Roche Madison Inc. Endosomolytic poly(vinyl ether) polymers
WO2003082303A1 (en) * 2002-03-29 2003-10-09 Wisconsin Alumni Research Foundation Polymeric micelle formulations of hydrophobic compounds and methods
EP2335694B1 (en) 2003-09-15 2018-06-13 NanoPharmaceuticals LLC Thyroid hormone analogs and methods of use
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
CA2549524A1 (en) * 2004-01-02 2005-07-28 Wisconsin Alumni Research Foundation Encapsulation of chemical compounds in fluorous-core and fluorous-inner-shell micelles formed from semifluorinated-block or fluorinated-block copolymers
EP2348096A3 (en) 2005-01-04 2011-11-09 Intezyne Technologies Inc. Synthesis of hybrid block copolymers and uses thereof
US9220788B2 (en) 2009-06-17 2015-12-29 Nanopharmaceuticals Llc Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
US20100209382A1 (en) 2005-09-16 2010-08-19 Ordway Research Institute, Inc. Polyphenol Conjugates as RGD-Binding Compounds and Methods of Use
US8212083B2 (en) 2006-04-27 2012-07-03 Intezyne Technologies, Inc. Heterobifunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof
US7560588B2 (en) 2006-04-27 2009-07-14 Intezyne Technologies, Inc. Poly(ethylene glycol) containing chemically disparate endgroups
US20080035667A1 (en) * 2006-06-07 2008-02-14 Osg Norwich Pharmaceuticals, Inc. Liquid delivery system
US20100015068A1 (en) * 2006-07-06 2010-01-21 Massachusetts Institute Of Technology Methods and Compositions For Altering Biological Surfaces
WO2008006097A2 (en) * 2006-07-07 2008-01-10 Intezyne Technologies Llc Covalent modification of metal surfaces
JP5274461B2 (ja) * 2006-08-18 2013-08-28 アローヘッド リサーチ コーポレイション ポリヌクレオチドのインビボ送達のためのポリ結合体
WO2008070284A2 (en) 2006-10-16 2008-06-12 Johnnie B. Byrd, Sr. Alzheimer's Center And Research Institute Amyloid beta peptides and methods of uses thereof
US8414927B2 (en) * 2006-11-03 2013-04-09 Boston Scientific Scimed, Inc. Cross-linked polymer particles
EP2099408B1 (en) * 2006-11-28 2016-10-05 Wisconsin Alumni Research Foundation Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics
US20100003336A1 (en) * 2006-12-01 2010-01-07 The Regents Of The University Of California Vesicles of self-assembling block copolymers and methods for making and using the same
WO2008070141A2 (en) * 2006-12-06 2008-06-12 Wisconsin Alumni Research Foundation Compositions for delivery of therapeutic agents
US20100297023A1 (en) * 2006-12-22 2010-11-25 Imuthes Limited University Of The Witwatersrand Lipid
CA2673133C (en) * 2006-12-22 2016-08-30 Clf Medical Technology Acceleration Program, Inc. Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US8900562B2 (en) * 2007-01-12 2014-12-02 Wisconsin Alumni Research Foundation Semi-fluorinated block copolymers for delivery of therapeutic agents
WO2008089487A2 (en) * 2007-01-19 2008-07-24 The Cleveland Clinic Foundation Carboxyethylpyrrole compounds and methods of their production
WO2008089485A2 (en) * 2007-01-19 2008-07-24 The Cleveland Clinic Foundation Carboxyethylpyrrole compounds and methods of their production
US7758635B2 (en) * 2007-02-13 2010-07-20 Boston Scientific Scimed, Inc. Medical device including cylindrical micelles
EP2131814A4 (en) * 2007-02-26 2011-08-03 Wisconsin Alumni Res Found POLYMIC MICROMS FOR THE RELEASE OF ACTIVE COMPOUNDS
US7618944B2 (en) * 2007-03-01 2009-11-17 Intezyne Technologies, Inc. Encapsulated amyloid-beta peptides
AU2008245404B2 (en) * 2007-04-30 2013-12-05 Intezyne Technologies, Inc. Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents
EP2152320A2 (en) * 2007-04-30 2010-02-17 Intezyne Technologies Incorporated Encapsulated contrast agents
US9084771B2 (en) 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
JP2011503067A (ja) * 2007-11-07 2011-01-27 マリンクロッド・インコーポレイテッド 生物学的適用のためのフォトニックシェルコアが架橋し、官能化されたナノ構造
WO2009073193A2 (en) * 2007-12-03 2009-06-11 The Johns Hopkins University Methods of synthesis and use of chemospheres
ES2648196T3 (es) 2008-02-07 2017-12-29 The University Of Washington Dispositivo aerosol circunferencial
US20090232762A1 (en) * 2008-03-11 2009-09-17 May Pang Xiong Compositions for delivery of therapeutic agents
US8034396B2 (en) 2008-04-01 2011-10-11 Tyco Healthcare Group Lp Bioadhesive composition formed using click chemistry
JP5317031B2 (ja) * 2008-05-07 2013-10-16 公立大学法人大阪府立大学 ヘッド−テイル型共重合体の中空ナノ微粒子
GB2471987B (en) 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2475183B (en) * 2008-06-04 2011-11-23 Gw Pharma Ltd Cannabinoids in combination with non-cannabinoid chemotherapeutic agent that are selective estrogen receptor modulators
KR101468268B1 (ko) * 2008-07-29 2014-12-02 나노캬리아 가부시키가이샤 약물 내포 액티브 타겟형 고분자 미셀, 의약 조성물
WO2010036973A1 (en) * 2008-09-25 2010-04-01 Comgenrx, Inc. Treatment of hyperproliferative disorders using cardiac glycosides
KR20130056348A (ko) * 2008-09-25 2013-05-29 인비보 테라퓨틱스 코포레이션 척수 외상, 염증, 및 면역 질환: 치료제의 국소적 제어 방출
CA2740125A1 (en) * 2008-10-09 2010-04-15 Northeastern University Multifunctional self-assembling polymeric nanosystems
AU2013204152B2 (en) * 2008-11-06 2016-04-14 Phaserx, Inc. Multiblock copolymers
KR20110095292A (ko) 2008-11-06 2011-08-24 유니버시티 오브 워싱톤 다중블록 공중합체
WO2010075332A1 (en) * 2008-12-23 2010-07-01 Charitable Leadership Foundation Small molecule ligands of the integrin rgd recognition site and methods of use
US8968733B2 (en) 2009-02-21 2015-03-03 Sofradim Production Functionalized surgical adhesives
US8535477B2 (en) 2009-02-21 2013-09-17 Sofradim Production Medical devices incorporating functional adhesives
US8648144B2 (en) 2009-02-21 2014-02-11 Sofradim Production Crosslinked fibers and method of making same by extrusion
US9039979B2 (en) 2009-02-21 2015-05-26 Sofradim Production Apparatus and method of reacting polymers passing through metal ion chelated resin matrix to produce injectable medical devices
US8956603B2 (en) 2009-02-21 2015-02-17 Sofradim Production Amphiphilic compounds and self-assembling compositions made therefrom
AU2010215936B2 (en) 2009-02-21 2015-03-05 Covidien Lp Medical devices having activated surfaces
WO2010095055A1 (en) 2009-02-21 2010-08-26 Sofradim Production Crosslinked fibers and method of making same using uv radiation
WO2010095052A2 (en) * 2009-02-21 2010-08-26 Sofradim Production Compounds and medical devices activated with solvophobic linkers
AU2010215931A1 (en) 2009-02-21 2011-10-13 Covidien Lp Medical devices having activated surfaces
EP2398850B1 (en) 2009-02-21 2018-08-22 Sofradim Production Medical devices with an activated coating
US8877170B2 (en) 2009-02-21 2014-11-04 Sofradim Production Medical device with inflammatory response-reducing coating
US8663689B2 (en) 2009-02-21 2014-03-04 Sofradim Production Functionalized adhesive medical gel
US8512728B2 (en) 2009-02-21 2013-08-20 Sofradim Production Method of forming a medical device on biological tissue
CA2753166A1 (en) 2009-02-21 2010-08-26 Sofradim Production Apparatus and method of reacting polymers by exposure to uv radiation to produce injectable medical devices
US9180107B2 (en) * 2009-03-31 2015-11-10 Nanopharmaceuticals Llc Combination treatment of cancer with cetuximab and tetrac
WO2010127271A1 (en) * 2009-04-30 2010-11-04 Intezyne Technologies, Incorporated Polymer micelles containing anthracylines for the treatment of cancer
US20100292432A1 (en) * 2009-04-30 2010-11-18 Intezyne Technologies, Incorporated Polymers for polynucleotide encapsulation
US8524784B2 (en) 2009-04-30 2013-09-03 Intezyne Technologies, Incorporated Polymer micelles containing anthracylines for the treatment of cancer
WO2010127159A2 (en) * 2009-04-30 2010-11-04 Intezyne Technologies, Incorporated Polymeric micelles for polynucleotide encapsulation
JP2012526049A (ja) * 2009-05-04 2012-10-25 インテザイン テクノロジーズ， インコーポレイテッド 腫瘍治療のためのｓｎ−３８を含有するポリマーミセル
EP2480207B1 (en) 2009-09-25 2016-11-09 Wisconsin Alumni Research Foundation Micelle encapsulation of therapeutic agents
WO2011062965A2 (en) 2009-11-18 2011-05-26 University Of Washington Through Its Center For Commercialization Targeting monomers and polymers having targeting blocks
WO2011102905A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion diagnostic delivery system
WO2011102906A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion delivery system
WO2011102904A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion therapeutic delivery system
PT2539451E (pt) 2010-02-24 2016-03-28 Arrowhead Res Corp Composições para entrega de arnsi dirigida ao alvo
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
WO2011113065A2 (en) * 2010-03-12 2011-09-15 Intezyne Technologies, Incorporated Pegylated polyplexes for polynucleotide delivery
WO2011117745A2 (en) 2010-03-25 2011-09-29 Sofradim Production Surgical fasteners and methods for sealing wounds
EP2550031B1 (en) 2010-03-25 2015-08-19 Sofradim Production Medical devices incorporating functional adhesives
FR2958649B1 (fr) * 2010-04-07 2012-05-04 Arkema France Copolymere a blocs issu de matieres renouvelables et procede de fabrication d'un tel copolymere a blocs
JP5848332B2 (ja) * 2010-05-14 2016-01-27 マリンクロッド エルエルシー 光学造影および療法のタンデムのための官能性架橋型ナノ構造物
US9247931B2 (en) 2010-06-29 2016-02-02 Covidien Lp Microwave-powered reactor and method for in situ forming implants
US8865857B2 (en) 2010-07-01 2014-10-21 Sofradim Production Medical device with predefined activated cellular integration
WO2012018594A2 (en) * 2010-07-26 2012-02-09 Scott & White Healthcare Plant-derived polysaccharides for delivery of rna-based therapies
EP2598178B1 (en) 2010-07-27 2018-07-11 Sofradim Production Polymeric fibers having tissue reactive members
PT2608800T (pt) 2010-08-23 2017-05-03 Amicrobe Inc Resumo
US10744151B1 (en) * 2010-12-01 2020-08-18 Gowey Research Group PLLC Micro-RNA profiling, compositions, and methods of treating diseases
US11344505B1 (en) 2010-12-01 2022-05-31 Gowey Research Group, Pllc Herbal formulations of carnivorous plants and methods for treating inflammation
US11414663B2 (en) 2010-12-01 2022-08-16 Gowey Research Group, Pllc Micro-RNA profiling, compositions, and methods of treating diseases
US10758578B2 (en) 2010-12-01 2020-09-01 Gowey Research Group PLLC Herbal formulations of carnivorous plants and methods for treating inflammation
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
BR112013022249B8 (pt) 2011-03-03 2022-10-25 Impel Neuropharma Inc Dispositivo de distribuição de droga nasal
US9498533B2 (en) 2011-04-04 2016-11-22 Board Of Regents Of The University Of Nebraska Drug delivery compositions and methods
US20140038879A1 (en) 2011-04-11 2014-02-06 Council Of Scientific & Industrial Research Surface induced disassembly of nano containers
CN103619485B (zh) 2011-05-09 2017-08-08 英倍尔药业股份有限公司 用于鼻腔药物递送的喷嘴
EP2714023A4 (en) * 2011-05-23 2014-12-24 Univ Massachusetts RETICULATED POLYMER NANO-ASSEMBLIES AND USES THEREOF
EP2543671A1 (de) * 2011-07-08 2013-01-09 cynora GmbH Querverknüpfung und Stabilisierung von organischen Metallkomplexen in Netzwerken
WO2013009928A1 (en) * 2011-07-11 2013-01-17 Organic Medical Research Cannabinoid formulations
US9901616B2 (en) 2011-08-31 2018-02-27 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
US8609146B2 (en) 2011-09-19 2013-12-17 Intezyne Technologies, Inc. Multi-block copolymers for the preparation of stabilized micelles
KR101334420B1 (ko) * 2011-11-17 2013-11-29 재단법인대구경북과학기술원 약물 전달을 위한 코어 크로스링킹된 고분자 마이셀 화합물 및 이의 제조방법
TWI568453B (zh) 2011-11-22 2017-02-01 原創生醫股份有限公司 具有螯合型複合微胞之藥物載體及其應用
RS63244B1 (sr) 2011-12-16 2022-06-30 Modernatx Inc Kompozicije modifikovane mrna
WO2013123298A1 (en) 2012-02-17 2013-08-22 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial trafficking of agents
WO2013124867A1 (en) 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules
EP2634193B1 (en) * 2012-02-29 2015-01-14 Enzypep B.V. Side-chain protected oligopeptide fragment condensation using subtilisins in organic solvents
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
CA2868391A1 (en) 2012-04-02 2013-10-10 Stephane Bancel Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same
US9944752B2 (en) 2012-04-11 2018-04-17 Intezyne Technologies, Inc. Block copolymers for stable micelles
US20140127271A1 (en) * 2012-04-11 2014-05-08 Intezyne Technologies, Inc. Block copolymers for stable micelles
US20140113879A1 (en) * 2012-04-11 2014-04-24 Intezyne Technologies, Inc. Block copolymers for stable micelles
AU2013201541B2 (en) * 2012-04-11 2014-08-14 Intezyne Technologies, Inc. Block copolymers for stable micelles
WO2014035465A1 (en) * 2012-08-28 2014-03-06 Original Biomedicals Co., Ltd. The controlled release method for a pharmaceutical composition composed of chelating complex micelles
US20140134601A1 (en) * 2012-11-09 2014-05-15 Korea University Research And Business Foundation Use of protein nanoparticle based hydrogel
KR101403191B1 (ko) * 2012-11-19 2014-06-02 가톨릭대학교 산학협력단 약물 전달을 위한 야누스 및 다중 결합 미셀 및 이의 제조 방법
WO2014141289A1 (en) 2013-03-12 2014-09-18 Amrita Vishwa Vidyapeetham University Photo - chemo composition on the basis of microcapsules with a core -shell structure
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9784730B2 (en) 2013-03-21 2017-10-10 University Of Washington Through Its Center For Commercialization Nanoparticle for targeting brain tumors and delivery of O6-benzylguanine
US11491154B2 (en) 2013-04-08 2022-11-08 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
WO2014179228A1 (en) 2013-04-28 2014-11-06 Impel Neuropharma Inc. Medical unit dose container
US9775928B2 (en) 2013-06-18 2017-10-03 Covidien Lp Adhesive barbed filament
GB2516814B (en) 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
CA2923029A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
FR3011550B1 (fr) * 2013-10-07 2016-11-18 Arkema France Copolymere a blocs polyamide et a bloc polyether
US20170080093A1 (en) * 2013-10-22 2017-03-23 Tyme, Inc. Tyrosine Derivatives And Compositions Comprising Them
US9585841B2 (en) * 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
US10060934B2 (en) 2013-11-18 2018-08-28 Nanopharmaceuticals Llc Methods for screening patients for resistance to angioinhibition, treatment and prophylaxis thereof
KR102252561B1 (ko) 2013-11-22 2021-05-20 미나 테라퓨틱스 리미티드 Ｃ/ｅｂｐ 알파 짧은 활성화 ｒｎａ 조성물 및 사용 방법
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
US10398663B2 (en) 2014-03-14 2019-09-03 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
US9622970B2 (en) * 2014-05-08 2017-04-18 Yaguang Liu Pharmaceutical composition containing lutein and antioxidant for treating and preventing human disease
US10653709B2 (en) 2014-05-19 2020-05-19 North Carolina State University Methods of folding a graft copolymer with dual anticancer drugs and related applications
EP3169693B1 (en) 2014-07-16 2022-03-09 ModernaTX, Inc. Chimeric polynucleotides
US20170210788A1 (en) 2014-07-23 2017-07-27 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
WO2016029043A1 (en) 2014-08-21 2016-02-25 The General Hospital Corporation Tumor necrosis factor superfamily and tnf-like ligand muteins and methods of preparing and using the same
US11298424B2 (en) 2014-10-01 2022-04-12 The Regents Of The University Of California Non-ionic and thermoresponsive diblock copolypeptide hydrogels for delivery of molecules and cells
CN104448300B (zh) * 2014-12-09 2017-01-11 西安医学院 低分子量l-聚谷氨酸-丝裂霉素c及其合成方法和应用
US10232050B1 (en) 2014-12-12 2019-03-19 Clemson University Multi-functional particles and methods of using the same
US11633355B2 (en) 2014-12-12 2023-04-25 Clemson University Research Foundation Multi-functional particles and methods of using the same
US9956300B2 (en) * 2015-03-18 2018-05-01 Duke Univerity Hydrogels formed from polypeptide micelles and methods of use thereof
FR3034423B1 (fr) * 2015-04-03 2019-05-31 Cnrs Dispersion aqueuse de particules d'au moins un polymere thermoplastique, son procede de preparation et ses applications, notamment pour l'ensimage de fibres de renfort
WO2016187264A1 (en) 2015-05-18 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Enhanced melanoma cancer prevention by novel melanotropins
US20160346408A1 (en) * 2015-05-26 2016-12-01 Intezyne Technologies Iron stabilized micelles as magnetic contrast agents
JP6753927B2 (ja) 2015-09-10 2020-09-09 インペル ニューロファーマ インコーポレイテッド 直列形経鼻送達デバイス
EP4349405A3 (en) 2015-10-22 2024-06-19 ModernaTX, Inc. Respiratory virus vaccines
CA3002912A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Nucleic acid vaccines for varicella zoster virus (vzv)
BR112018008090A2 (pt) 2015-10-22 2018-11-13 Modernatx Inc vacina de vírus do herpes simplex.
CN108472354A (zh) 2015-10-22 2018-08-31 摩登纳特斯有限公司 呼吸道合胞病毒疫苗
WO2017070620A2 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Broad spectrum influenza virus vaccine
AU2016342045A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Human cytomegalovirus vaccine
RS63135B1 (sr) 2015-12-23 2022-05-31 Modernatx Inc Postupci upotrebe polinukleotida koji kodiraju ox40 ligand
US20190241658A1 (en) 2016-01-10 2019-08-08 Modernatx, Inc. Therapeutic mRNAs encoding anti CTLA-4 antibodies
KR101905010B1 (ko) 2016-04-19 2018-10-08 앱티스 주식회사 코엔자임 q10 가용화 조성물 및 이의 제조방법
CA3026504A1 (en) 2016-06-07 2017-12-14 Nanopharmaceuticals, Llc Non-cleavable polymer conjugated with .alpha..nu..beta.3 integrin thyroid antagonists
US10548908B2 (en) * 2016-09-15 2020-02-04 Nostopharma, LLC Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification
US10143689B2 (en) 2017-02-08 2018-12-04 Interzyne Technologies, Inc. SN-38 loaded iron crosslinked micelle and methods thereof
CN110591078B (zh) * 2017-06-26 2021-11-05 苏州大学 还原/pH双重响应性阿霉素前药的制备方法
EP3679138B1 (en) 2017-09-08 2023-03-22 MiNA Therapeutics Limited Hnf4a sarna compositions and methods of use
US20200208152A1 (en) 2017-09-08 2020-07-02 Mina Therapeutics Limited Stabilized sarna compositions and methods of use
US20210236644A1 (en) 2017-11-10 2021-08-05 Cocoon Biotech Inc. Ocular applications of silk-based products
WO2019104205A1 (en) 2017-11-21 2019-05-31 Impel Neuropharma, Inc. Intranasal device with dip tube
WO2019104192A1 (en) 2017-11-21 2019-05-31 Impel Neuropharma, Inc. Intranasal device with inlet interface
WO2019113461A1 (en) * 2017-12-08 2019-06-13 Western University Of Health Sciences Lipid emulsified drug delivery systems for chemoprevention and treatment
WO2019129657A1 (en) 2017-12-28 2019-07-04 Fundació Hospital Universitari Vall D'hebron - Institut De Recerca Actively targeted polymeric micelles for drug and gene delivery
AU2019205318B2 (en) 2018-01-05 2022-02-03 Impel Pharmaceuticals Inc. Intranasal delivery of dihydroergotamine by precision olfactory device
JP2021509677A (ja) 2018-01-05 2021-04-01 インペル ニューロファーマ インコーポレイテッド 精密嗅覚装置によるオランザピンの鼻孔間送達
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
US11566246B2 (en) 2018-04-12 2023-01-31 Mina Therapeutics Limited SIRT1-saRNA compositions and methods of use
CN109111582A (zh) * 2018-06-14 2019-01-01 哈尔滨工业大学无锡新材料研究院 一种聚醚胺-戊二酸共聚物胶团及其制备方法
CN112955134A (zh) 2018-07-19 2021-06-11 英倍尔药业股份有限公司 用于治疗帕金森氏病的左旋多巴和多巴脱羧酶抑制剂的呼吸道递送
EP3833762A4 (en) 2018-08-09 2022-09-28 Verseau Therapeutics, Inc. OLIGONUCLEOTIDE COMPOSITIONS FOR TARGETING CCR2 AND CSF1R AND THEIR USES
KR20210109007A (ko) 2019-01-03 2021-09-03 임펠 뉴로파마 인코포레이티드 비강 약물 전달 장치
US20220211740A1 (en) 2019-04-12 2022-07-07 Mina Therapeutics Limited Sirt1-sarna compositions and methods of use
EP3969085A4 (en) 2019-05-17 2023-06-21 Impel Pharmaceuticals Inc. DISPOSABLE NASAL DELIVERY DEVICE
KR102376945B1 (ko) * 2019-12-19 2022-03-21 상지대학교산학협력단 파킨슨병용 약제학적 조성물 및 그 치료제
CN112999151B (zh) * 2019-12-19 2024-03-19 鲁南制药集团股份有限公司 一种口服用紫杉醇复合胶束
CN113024789B (zh) * 2019-12-23 2023-01-06 福建省紫杉园药业有限责任公司 一种交联聚合物胶束及其制备方法和应用
CN111228301A (zh) * 2020-01-14 2020-06-05 哈尔滨医科大学 一种用于治疗血管生成介导疾病的复方制剂及其制备方法和应用
CN111297876B (zh) * 2020-01-16 2021-04-27 武汉理工大学 一种塞来昔布胶束和和厚朴酚胶束药物联用控释系统及其制备方法
US12090206B2 (en) 2020-04-23 2024-09-17 The Regents Of The University Of California Compositions comprising tri- and penta-block synthetic copolypeptide hydrogels
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
GB2603454A (en) 2020-12-09 2022-08-10 Ucl Business Ltd Novel therapeutics for the treatment of neurodegenerative disorders
JP2024501974A (ja) * 2020-12-28 2024-01-17 公益財団法人川崎市産業振興財団 ポリイオンコンプレックスミセル
US20240175033A1 (en) 2021-03-26 2024-05-30 Mina Therapeutics Limited TMEM173 saRNA Compositions and Methods of Use
KR102701406B1 (ko) * 2021-10-18 2024-08-30 재단법인대구경북과학기술원 토코페롤을 포함하는 활성 산소 반응형 믹토암 양친매성 화합물, 이의 제조 방법, 및 이를 이용한 약물 전달체
WO2023099884A1 (en) 2021-12-01 2023-06-08 Mina Therapeutics Limited Pax6 sarna compositions and methods of use
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists
GB202117758D0 (en) 2021-12-09 2022-01-26 Ucl Business Ltd Therapeutics for the treatment of neurodegenerative disorders
WO2023161350A1 (en) 2022-02-24 2023-08-31 Io Biotech Aps Nucleotide delivery of cancer therapy
WO2023170435A1 (en) 2022-03-07 2023-09-14 Mina Therapeutics Limited Il10 sarna compositions and methods of use
CN114957733B (zh) * 2022-05-12 2024-04-05 安徽工程大学 Boc-苯丙氨酸改性淀粉纳米粒子及其制备方法和在疏水药物负载的应用
CN114920869B (zh) * 2022-05-24 2023-07-14 太原工业学院 两亲性精氨酸嵌段环丙沙星共聚物、纳米颗粒及其制备方法和应用
WO2024134199A1 (en) 2022-12-22 2024-06-27 Mina Therapeutics Limited Chemically modified sarna compositions and methods of use

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2240547A (en) 1990-01-31 1991-08-07 Ciba Geigy Ag New compositions
KR940003548U (ko) * 1992-08-14 1994-02-21 김형술 세탁물 건조기
DE69638137D1 (de) * 1995-09-07 2010-04-15 Univ Georgia Therapeutische azidverbindungen
JPH11335267A (ja) 1998-05-27 1999-12-07 Nano Career Kk 水難溶性薬物を含有するポリマーミセル系
JP4659937B2 (ja) * 1999-11-19 2011-03-30 ナノキャリア株式会社 コア−シェル構造のポリイオンコンプレックスミセル
JP3523821B2 (ja) * 2000-02-09 2004-04-26 ナノキャリア株式会社 薬物が封入されたポリマーミセルの製造方法および該ポリマーミセル組成物
FR2814951B1 (fr) * 2000-10-06 2003-01-17 Flamel Tech Sa Suspension colloidale de particules submicroniques de vectorisation de principes actifs hydrophiles (insuline) et leur mode de preparation
FR2822834B1 (fr) * 2001-04-02 2005-02-25 Flamel Tech Sa Suspension colloidale de nanoparticules a base de copolymeres amphiphile pour la vectorisation de principes actifs et leur mode de preparation
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
US6881484B2 (en) * 2001-05-30 2005-04-19 Mitsubishi Kagaku Iatron, Inc. Core-shell particle including signal-generating substance enclosed therein and process for producing the same
US20050249786A1 (en) * 2001-09-28 2005-11-10 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
US6780324B2 (en) * 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
JP2004010479A (ja) * 2002-06-03 2004-01-15 Japan Science & Technology Corp ブロック共重合体とアンスラサイクリン系抗癌剤を含む新規固型製剤及びその製造法
JP2004018494A (ja) * 2002-06-19 2004-01-22 Japan Science & Technology Corp ブロック共重合体−薬剤複合体の製造法
JP4535229B2 (ja) * 2003-05-08 2010-09-01 国立大学法人 東京大学 ポリエチレングリコール−ポリカチオンブロック共重合体
JP4763459B2 (ja) 2003-05-29 2011-08-31 株式会社東京大学Ｔｌｏ 安定化高分子ミセル
JP2006199590A (ja) 2003-09-04 2006-08-03 Nano Career Kk 水溶性の塩基性薬物内包ナノ粒子含有組成物
US7311901B2 (en) * 2003-10-10 2007-12-25 Samyang Corporation Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
JP4920593B2 (ja) * 2004-10-25 2012-04-18 インテザイン テクノロジーズ， インコーポレイテッド ヘテロ二官能性ポリ（エチレングリコール）およびそれらの使用
IL165260A0 (en) 2004-11-16 2005-12-18 Yissum Res Dev Co Polymeric nano-shells
EP2348096A3 (en) * 2005-01-04 2011-11-09 Intezyne Technologies Inc. Synthesis of hybrid block copolymers and uses thereof

Also Published As

Publication number Publication date
JP4390845B2 (ja) 2009-12-24
US8263665B2 (en) 2012-09-11
EP1907444A2 (en) 2008-04-09
US20100159020A1 (en) 2010-06-24
US8263663B2 (en) 2012-09-11
US20110091534A1 (en) 2011-04-21
US20130195987A1 (en) 2013-08-01
KR20080015070A (ko) 2008-02-18
US8299128B2 (en) 2012-10-30
MX2007012157A (es) 2008-03-14
AU2006231452A1 (en) 2006-10-12
JP2008537943A (ja) 2008-10-02
US7638558B2 (en) 2009-12-29
WO2006107903A3 (en) 2007-02-15
US8426477B1 (en) 2013-04-23
IL186254A (en) 2012-04-30
US8779008B2 (en) 2014-07-15
CA2603853C (en) 2013-11-19
AU2006231452B2 (en) 2011-05-26
EP1907444B1 (en) 2009-08-19
US20110092668A1 (en) 2011-04-21
IL186254A0 (en) 2008-01-20
WO2006107903A2 (en) 2006-10-12
NZ562064A (en) 2011-03-31
DE602006008625D1 (de) 2009-10-01
US20060240092A1 (en) 2006-10-26
KR101288729B1 (ko) 2013-07-23
CA2603853A1 (en) 2006-10-12
ATE440117T1 (de) 2009-09-15

Similar Documents

Publication Publication Date Title
ES2332062T3 (es) Micelas polimericas para el suministro de farmacos.
JP2008537943A5 (US07638558-20091229-C00193.png)
ES2432641T3 (es) Micelas híbridas de copolímero en bloque con estereoquímica mixta para encapsulación de agentes hidrófobos
ES2560235T3 (es) Copolímeros en bloque para micelas estables
US20100278927A1 (en) Polymeric micelles for polynucleotide encapsulation
JP2010526091A (ja) 癌の処置のための生物学的な標的基の改変
JP2010526091A5 (US07638558-20091229-C00193.png)
WO2011068916A1 (en) Pegylated polyplexes for polynucleotide delivery
CN104245794A (zh) α-氨基脒聚合物及其用途
Xu et al. Design, synthesis and evaluation of spermine-based pH-sensitive amphiphilic gene delivery systems: Multifunctional non-viral gene carriers
Wang et al. Tuning the architecture of polymeric conjugate to mediate intracellular